Hormone therapy to shrink early uterine cancer in young women
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether combining two hormone medicines can treat early endometrial (uterine) cancer while helping preserve the uterus and future fertility. You may be eligible if your cancer is early and limited, with no spread seen on scans, and you can safely take these medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are able to sign informed consent to join the study
- You have confirmed early endometrial cancer: endometrioid type, grade 1, and no muscle-layer (myometrium) invasion seen on tests
- Scans (enhanced MRI/CT and a transvaginal ultrasound) show no spread outside the uterus
- You want to keep fertility/your uterus and agree to regular follow-up visits at the study hospital
- You can safely take the study hormone medicines (including letrozole and triptorelin) and are not pregnant or trying to conceive during screening
- You have no major exclusions like prior recurrence, other cancer types, major liver/kidney problems, recent hormone treatment, blood-clot history, recent serious illness (like stroke/heart attack), or heavy smoking (>15 cigarettes/day)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at a fertility-preserving treatment plan for people with early-stage endometrial cancer who want to keep the ability to have children. It may help you avoid surgery that removes fertility, if you meet the trial’s safety and eligibility rules.
This trial tests whether adding GnRH medicine and letrozole to standard progestin treatment can better control early, low-risk endometrial cancer or atypical hyperplasia in people who are not obese. It may help some patients avoid progression while keeping the uterus, especially for those wanting future fertility.
This study tests whether certain treatments can help women aged 18-45 with early-stage endometrial cancer or precancerous changes keep their ability to have children. It uses imaging scans to make sure the cancer hasn't spread.
This trial tests a tailored approach to preserve fertility in women with early-stage endometrial cancer, using medications like hormones and immunotherapy based on the tumor's molecular subtype. It aims to avoid hysterectomy and keep the uterus intact.
This trial tests a combination of two hormone-blocking drugs (GnRHa plus letrozole) for women with early-stage, obesity-related endometrial cancer who haven't responded well to standard hormone therapy alone. The goal is to preserve the uterus and fertility while controlling the cancer.
This trial studies a weight-management approach plus a progesterone-releasing IUD (LNG-IUS) and megestrol to treat endometrial atypical hyperplasia, a high-risk precancer of the uterine lining. It may help shrink or control the abnormal cells while supporting fertility or keeping the uterus.
Hear when a new Endometrial Neoplasm Malignant Stage I trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.